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ABSTRACT
Intrahepatic cholangiocarcinoma (ICC) is an aggressive and lethal malignancy 
with limited therapeutic options. Trabectedin has a high antitumor activity in preclinical 
models of biliary tract carcinoma (BTC), being a promising alternative treatment. Here, 
we studied the effect of trabectedin at transcriptomic level on an ICC patient derived 
xenograft (PDX) and on the derived cell line, MT-CHC01. Further, putative targets of 
trabectedin were explored in the in vitro model. In vitro, trabectedin inhibited genes 
involved in protein modification, neurogenesis, migration, and motility; it induced the 
expression of genes involved in keratinization, tissues development, and apoptotic 
processes. In the PDX model, trabectedin affected ECM-receptor interaction, focal 
adhesion, complement and coagulation cascades, Hedgehog, MAPK, EGFR signaling 
via PIP3 pathway, and apoptosis. Among down-regulated genes, we selected SYK and 
LGALS1; their silencing caused a significantly reduction of migration, but did not affect 
proliferation in in vitro models. In MT-CHC01 cells, 24 microRNAs were deregulated 
upon drug treatment, while only 5 microRNAs were perturbed by trabectedin in PDX. 
The target prediction analysis showed that SYK and LGALS1 are putative targets of 
up-regulated microRNAs. In conclusion, we described that trabectedin affected genes 
and microRNAs involved in tumor progression and metastatic processes, reflecting 
data previously obtained at macroscopically level; in particular, we identified SYK and 
LGALS1 as new putative targets of trabectedin.
INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is the second 
most common liver cancer type [1, 2]. It is aggressive and 
with poor prognosis, with limited therapeutic options. 
Patients with unresectable disease (70-90%) have a poor 
prognosis with a survival of less than 12 months following 
diagnosis [3, 4]. Conventional therapy gives only marginal 
benefit [5]. Several dosage schedules of single-agent 
gemcitabine (gem) have been tested obtaining response 
rates of about 20%. To date, the standard of treatment is 
the combination of gem and cisplatin; a meta-analysis 
conducted by Valle and collaborators demonstrated that 
this association gave a significant survival advantage, 
compared to gem alone (progression free survival, PFS, 
of 8 vs. 6.7 months; overall survival, OS of 11.6 months 
vs 8.0 months) [6]. These data demonstrate the lack 
of effective therapies and consequently the need of 
identifying alternative therapeutic approaches.
Trabectedin (Ecteinascidin-743 or ET-743) is a 
marine derived compound isolated from the Caribbean 
tunicate Ecteinascidia Turbinata with a potent antitumor 
effect, based on a particular mechanism of action. It acts 
as an alkylating agent by binding to the minor groove of 
DNA, inducing double-strand DNA breaks and interacting 
with transcription factors, in particular the NF-Y which 
interacts with the CCAAT box [7–10]. Recent data suggest 
that the nucleotide excision repair mechanism plays a key 
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role in trabectedin antitumor activity. It was described 
that trabectedin could specifically interact with the DNA 
transcription-coupled nucleotide excision repair (TC-NER) 
process [11], which in normal conditions repairs DNA 
adducts caused by UV rays, cisplatin or others anticancer 
agents by involvement of proteins belonging to family 
of XP11 and NER factors. Thus, the double-strand 
DNA breaks formed are more persistent if there is loss 
of homologous DNA repair [12]. Further, it has been 
described that trabectedin had a potent antitumor activity 
both on tumor cells as well as on microenvironment [13]. 
It is also known that trabectedin causes a marked decrease 
in the production of several cytokines and chemokines 
secreted by monocytes/macrophages and tumor cells. 
For example, trabectedin treatment down-regulates 
the expression of IL-6 (Interleukin-6), CCL2, CXCL8, 
Angiopoietin 2 or VEGF (Vascular endothelial growth 
factor) [14].
Trabectedin has been approved for treatment of 
ovarian cancer and soft-tissue sarcoma with significant 
activity in liposarcomas, leiomyosarcomas, and Ewing 
sarcoma, both as a single agent and in combination 
with other drugs [15–18]. Trabectedin has also shown 
promising pre clinical activity against other different 
cancer cell lines in vitro and transplantable in vivo human 
tumor xenografts [19–28].
We have recently demonstrated that trabectedin 
has an antitumor activity both in vitro and in vivo in 
preclinical models of human biliary tract carcinoma 
(BTC). We reported that trabectedin inhibits BTC in 
vitro cell growth and causes a significant delay of tumor 
growth in vivo in mouse models of human BTC, EGI-1 
extrahepatic cholangiocarcinoma xenograft and a new 
intrahepatic cholangiocarcinoma (ICC) patient-derived 
tumor xenograft (PDX) [19], causing a decrease of 
tumor proliferating cells and tumor vessel formation. 
Transcriptomic analysis revealed that, upon trabectedin 
treatment, there is a deregulation of genes involved in 
IL-6, Sonic Hedgehog and Wnt signaling pathways, all 
related to cholangiocarcinogenesis.
Here, we used a human intrahepatic 
cholangiocarcinoma paired PDX and cell line model to 
investigate the changes in gene and microRNA expression 
in response to trabectedin. The aim of this study is the 
identification of differentially expressed genes, of related 
biological pathways and microRNAs which may be 
relevant as specific targets of trabectedin. Furthermore, we 
studied the effective role of two genes as putative targets 
of trabectedin in the in vitro model.
RESULTS
Transcriptomic profiles of MT-CHC01 cell line 
and PDX upon trabectedin treatment
Changes in the expression of various genes were 
observed upon in vitro trabectedin treatment in MT-CHC01 
cells. We applied a filter on LogFC value and considered 
for the analysis only probes with a Log FC <-1 or > 1. 
Upon trabectedin treatment, 1,254 differentially expressed 
gene transcripts were identified, of which 948 were down- 
and 306 up-regulated. Gene Ontology was performed 
using DAVID Annotation tool; Supplementary Table S1 
summarized the biological processes significantly enriched 
within down-and up-regulated probes. Trabectedin 
is able to negatively influence regulation of GTPase 
activity, processes related to neurogenesis, migration, 
cell adhesion, and microtubules organization. On the 
other hand, trabectedin induces the expression of genes 
involved in keratinization, epidermis, endoderm and tissue 
development, and apoptotic processes.
The same analysis was performed to identify 
pathways enriched within down- and up-regulated genes 
(Kegg database) (Supplementary Table S2); the most 
significant down-regulated pathway includes genes 
involved in focal adhesion.
The same filter applied to MT-CHC01 was used for 
PDX data yielding only 28 differentially expressed genes. 
Relaxing cut-offs (Log FC <0.58 or >0.58 and p-value 
<0.05), we obtained 1,346 differentially expressed genes 
of which 628 were down- and 718 up-regulated.
As shown in Supplementary Table S3, Gene 
Ontology revealed a globally down-regulation of 
genes involved in eye, organ and skin morphogenesis, 
tissue development, immune response and regulation 
of angiogenesis. In contrast, there is an up-regulation 
of genes involved in inflammation process, muscle 
development, negative regulation of signal transduction, 
and different biosynthetic processes.
Further, we found that down-regulated genes caused 
an enrichment of pathways involved in ECM-receptor 
interaction, focal adhesion, complement and coagulation 
cascades, and Hedgehog signaling pathways. On the 
contrary, for up-regulated genes we found an enrichment 
of MAPK pathway, EGFR signaling via PIP3, and 
apoptosis (Supplementary Table S4).
The next step was the identification of common 
deregulated genes between the in vitro and in vivo 
models. We found 223 concordant overlapping genes, of 
which 75 down-and 148 up-regulated after trabectedin 
treatment (Supplementary Table S5A-S5B). An 
unsupervised cluster analysis of this gene set shows a 
separation between trabectedin-treated from not treated 
samples (Figure 1).
The Gene Ontology analysis was performed on 
down-and up-regulated genes separately (Table 1).
The ECM-receptor transition pathway, Systemic 
lupus erythematosus, Hedgehog signaling pathway, and 
Basal cell carcinoma (p <0.05) are the common pathways 
enriched by down-regulated genes. No statistically 
significant common pathways are enriched by up-
regulated genes.
In order to validate expression data, we analyzed by 
RT-qPCR the expression of the common down-regulated 
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CLDN2, CDH2, WNT7B, PMEPA1, NAV2, SYK, 
LGALS1, and the up-regulated ATF3, NOV, CD68, RASD 
genes. The same trend of expression was revealed for all 
genes in both MT-CHC01 and PDX after trabectedin 
treatment, as shown in Figure 2A-2B.
SYK and LGALS1 are putative targets of 
trabectedin
In order to investigate possible new targets of 
trabectedin, we selected two genes, SYK and LGALS1, 
resulted down-regulated by drug treatment in both models. 
To verify if their silencing exerted the same effect of 
trabectedin, we silenced them at first in MT-CHC01 cells. 
Both qRT-PCR and Western Blot analysis, either upon 
trabectedin treatment or after silencing with single specific 
siRNA or a pool of them, showed the inhibition of targeted 
genes (Figure 3).
To investigate the functional role of these genes, 
we performed cell viability and migration assays. Cell 
viability of MT-CHC01 cells is significant decreased 
after trabectedin treatment, with an IC50 value of 1.85 
nM (Supplementary Figure S1 Panel A-B). Further, 
trabectedin is able to block cell cycle in G0/G1 and to 
Figure 1: Unsupervised cluster analysis of common modulated genes between in vitro and in vivo model. A clear separation 
between trabectedin treated and not treated samples is found.
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Table 1: The Gene Ontology analysis on common down- and up-regulated genes
Category (BP-5) Name p-value Expression upon trabectedin
0000988 tissue development 0.000884 down
0009887 organ morphogenesis 0.001 down
0051969 regulation of transmission of nerve impulse 0.002 down
0031644 regulation of neurological system process 0.003 down
0043588 skin development 0.005 down
0010556 regulation of macromolecule biosynthetic process 0.00001 up
0045449 regulation of transcription 0.00003 up
0031326 regulation of cellular biosynthetic process 0.00004 up
0010468 regulation of gene expression 0.00005
0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 0.0001 up
0045596 negative regulation of cell differentiation 0.003 up
BP-5: biological process level 5
Figure 2: Gene expression validation by qRT-PCR of selected genes altered in microarray analysis. Panel A shows 
down-regulated genes and Panel B up-regulated genes after trabectedin treatment. X axis: gene expression of MT-CHC01 and PDX, 
respectively. Y axis: 2-ΔΔCt for qRT-PCR.
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induce apoptosis after 48 hours of trabectedin treatment 
(Supplementary Figure S1, Panel C-D).
Conversely, the knock-down of single genes or 
their combination does not decrease the proliferation 
of MT-CHC01 cells (data not shown). Cell migration, 
significantly reduced by trabectedin treatment, is 
statistically significant inhibited also by silencing of SYK 
and LGALS1; the simultaneous silencing of target genes 
potentiates the anti-migratory effect (Figure 4).
To enforce these data, we repeated the same 
experiments on the ECC cell line WITT. Both qRT-PCR 
and Western Blot analysis demonstrated that trabectedin 
inhibited the expression of targets, as well as their 
silencing (Figure 5).
Similarly to the MT-CHC01, single and combined 
knock-down of SYK and LGALS1 reduced cell migration 
in a statistical significant manner (Figure 6), but did not 
have effect on proliferation (data not shown).
Trabectedin affects the expression of microRNAs 
involved in apoptosis and tumor progression
MicroRNA profiling of MT-CHC01 cells identified 
24 deregulated microRNAs upon trabectedin treatment, 
either up or down-regulated. Supplementary Table S6 
summarizes these microRNAs and their known role in 
cancerogenesis. Globally, upon trabectedin treatment, we 
found a deregulation of microRNAs involved in tumor 
progression, proliferation and migration, both as direct or 
indirect way. In particular, three microRNAs (miR-21-3p, 
miR-21-5p and miR-31-3p) have already been described 
as involved and up-regulated in BTC [29–31]; in our 
setting, they were inhibited by trabectedin, suggesting 
that they could represent candidate targets of this drug. 
Using the MiRpath program and the Pathway Intersection 
algorithm, which provides the pathways affected by the 
intersection of predicted targets by up/down-regulated 
Figure 3: Panel A: qRT-PCR quantification and Western Blot analysis of SYK and LGALS1 after trabectedin (5 nM) treatment on MT-
CHC01 cells. Panel B and C: qRT-PCR quantification and Western Blot analysis of SYK and LGALS1, respectively, after silencing. NT: 
not treated; OLIGO: cells treated with oligofectamine; siRNA CN: cells treated with negative control siRNA; siRNA1 and siRNA2: two 
different siRNA for SYK or LGALS; COMBO: combination of siRNA1 and siRNA2.
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microRNAs, we did not find any common pathways for 
both up-and down-regulated microRNAs. Considering up- 
and down-regulated microRNAs separately, we performed 
a pathway union analysis, which used an algorithm able 
to predict all the significant pathways targeted by selected 
microRNAs. As shown in Figure 7, down-regulated 
microRNAs (Panel A) affected in a statistically significant 
way the focal adhesion, ECM-receptor interaction, protein 
digestion and absorption, MAPK, PI3K-Akt, ERBB 
signaling pathways. Considering up-regulated microRNAs 
(Panel B), we found many affected pathways such as 
glycosphingolipid biosynthesis, lysine degradation, 
calcium signaling, MAPK and Hedgehog pathways.
The analysis performed on PDX model showed a 
deregulation of only five microRNAs, two up-regulated 
(miR-4284 and miR-375) and three down- (miR-22-3p, 
let-7c, and miR-214-3p). Figure 8 summarizes pathways 
affected by down-(Panel A) and up-regulated (Panel B) 
microRNAs using the Pathway Union algorithm, which 
evaluated the probability that the examined pathways 
are significantly enriched for gene targets of at least one 
microRNA.
Further, we revealed that miR-4284 was up-
regulated in both in vitro and in vivo models after 
trabectedin treatment. Validation of the microRNAs 
expression was obtained by RT-qPCR (Supplementary 
Figure S2).
MicroRNA-gene targets interaction analysis
To verify if there were interactions among the 
microRNA signature and the common modulated 
genes, we used miRWalk 2.0 database. We considered 
as significant the interactions predicted by at least 
4 databases. As shown in Figure 9, we found that up-
regulated microRNAs has 13,748 predictive targets, 
Figure 4: Wound healing assay. Panel A: representative images of MT-CHC01 wound closure upon different conditions. NT: Not 
treated; OLIGO: treated with oligofectamine; siRNA CN: treated with negative control siRNA; siRNA LGALS1 and SYK: treated with 
specific siRNA for LGALS1 and SYK, respectively; siRNA combo: simultaneous treatment with siRNA for LGALS1 and SYK; TRAB: 
treatment with 5 nM of trabectedin. T0: time of wound. Panel B: Statistical analysis of percentage of wound closure; Bars representing the 
area of closure at different conditions; 100% corresponds to the area at the time of wounding
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of which 50 down-regulated overlapped to our gene 
signature. On the contrary, down-regulated microRNAs 
are able to interact with 12,935 genes, of which 66 up-
regulated genes belonged to our dataset.
Interestingly, the microRNA-target prediction 
analysis showed that SYK is a putative target of all up-
regulated microRNAs, while LGALS1 is a predicted target 
only of miR1207-5p and miR1225-5p.
DISCUSSION
BTC is an aggressive neoplasia with a complex 
molecular pathogenesis; the current clinical approaches 
are limited and the poor prognosis, due also to the scarce 
therapeutic options, encourages the evaluation of new 
drugs. Trabectedin is a promising chemotherapeutic 
agent already used in clinical practice in different cancer 
types. Our group previously demonstrated that trabectedin 
has a high antitumor activity in BTC preclinical 
models, significantly slowing tumor growth, inhibiting 
proliferation and neovascularization processes, suggesting 
its potential as alternative chemotherapy option. Here, we 
studied the global effect of trabectedin on transcriptome in 
the paired xenopatient-cell line model.
Trabectedin is able to negatively influence the 
expression of genes involved in migration, invasion, 
motility, and epithelial to mesenchymal transition (EMT), 
confirming the important role of trabectedin in inhibiting 
angiogenesis and metastatic processes demonstrated 
in other malignancies [19, 28, 32–34]. Interestingly, 
we observed a down-regulation of genes involved in 
neurogenesis and regulation of neurological processes; 
it has been demonstrated that neurons and glial cells not 
only lead to higher cancer cell proliferation at the tumor 
invasion front, but also further enhance angiogenesis and 
neurogenesis in tumors [35].
On the contrary, trabectedin treatment is able to 
induce the expression of genes involved in p53 pathway, 
previously described by Martinez and collaborators [36], 
demonstrating that the drug induced the overexpression 
of genes related to stress and DNA damage, such as p53, 
CDKN1A, and ATF3. Moreover, it is able to induce the 
expression of genes involved in apoptotic and cell death 
processes, underlying the high therapeutic role of this 
drug. An overexpression of RASD1 seems to increase 
apoptosis via mitochondrial apoptosis pathway in prostate, 
breast, and lung cancer cell lines [37, 38]. IFIT2 is a 
tumor suppressor gene in gastric cancer [39], promoting 
Figure 5: Panel A: qRT-PCR quantification and Western Blot analysis of SYK and LGALS1 after trabectedin (5 nM) 
treatment on WITT cells. Panel B and C: qRT-PCR quantification and Western Blot analysis after silencing of SYK and LGALS1. NT: 
not treated; OLIGO: cells treated with oligofectamine; siRNA CN: cells treated with negative control siRNA; siRNA1 and siRNA2: two 
different siRNA for SYK of LGALS 1; COMBO: combination of siRNA1 and siRNA2.
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apoptosis and cell death. In our models, these genes are 
induced by trabectedin treatment, supporting the apoptotic 
process as previously demonstrated in vitro [19].
We evidenced that trabectedin perturbes genes 
involved in different cellular processes, among which 
the regulation of proliferation and migration. For this 
reason, we selected two down-regulated genes, SYK 
and LGALS1 to investigate if their suppression could 
reflect the effect of trabectedin on these processes. SYK 
is a non-receptor tyrosine kinase expressed in a variety 
of tissues, in particular in hematopoietic cells. Its role 
in cancer progression is controversial; in breast cancer 
it has a tumor suppressor role, while in head and neck 
and prostate cancer acted as an oncogene [40–42]. The 
role of LGALS1, a member of the lectin superfamily, is 
more defined; it is involved in different cellular function, 
as transduction, protein-protein interactions, cell-cycle 
progression, apoptosis, sustained proliferative signaling, 
resistance to cell death signals, evasion of immune 
surveillance, induction of angiogenesis, and activation 
of the metastatic potential. It is over-expressed in colon, 
liver, pancreatic cancer, in ICC and in their surrounding 
stroma cells; its overexpression seems to be associated 
with neoplastic progression and proliferative activities 
[43–46]. The silencing of each gene separately produced 
a statistically significant inhibition of migration, but 
not effect on proliferation. The simultaneous inhibition 
of these targets potentiates the anti-migratory effect, 
suggesting a crosstalk between SYK and LGALS1. 
In the work of Fulcher and collaborators, it has been 
demonstrated that Gal1, the protein encoded by LGALS1, 
induced cell activation and migration through the 
phosphorylation of Syk in dendritic cells [47]. The lack of 
inhibition of proliferation demonstrated that the silencing 
of these genes is not sufficient to mimic trabectedin effect, 
suggesting that a more complex mechanism of drug-targets 
Figure 6: Wound healing assay. Panel A: representative images of WITT wound closure upon different conditions. NT: Not treated; 
OLIGO: treated with oligofectamine; siRNA CN: treated with negative control siRNA; siRNA LGALS1 and SYK: treated with specific 
siRNA for LGALS1 and SYK, respectively; siRNA combo: simultaneous treatment with siRNA for LGALS1 and SYK; TRAB: treatment 
with 5 nM of trabectedin. T0: time of wound. Panel B: Statistical analysis of percentage of wound closure; Bars representing the area of 
closure at different conditions; 100% corresponds to the area at the time of wounding.
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Figure 7: Pathways union analysis of up- A. and down- B. regulated microRNAs separately upon trabectedin treatment of MT-CHC01 
cells.
Figure 8: Enriched pathways within up-regulated A. and down-regulated B. microRNAs upon trabectedin treatment of PDX.
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regulates cell growth. The role of trabectedin on SYK 
and LGALS1 inhibition is confirmed in the extrahepatic 
cell line WITT, with a significant reduction of migration 
ability, supporting our hypothesis that they are putative 
targets of this drug.
MicroRNA expression revealed a major number 
of alterations in the in vitro model. MiR-21-3p, miR-21-
5p and miR-31-3p have already been described in BTC, 
in particular they are up-regulated in ICC [31]. In our 
models, after trabectedin treatment they are significantly 
down-regulated, making them putative targets of the 
drug. The same mechanism could be supposed for 
miRNA 331-3p, down-regulated by trabectedin and 
demonstrated to promote proliferation and EMT in 
hepatocellular carcinoma [48]. On the contrary, miR-
494-3p is up-regulated after drug treatment; in a previous 
work of Shen and collaborators, they demonstrated that 
a constitutive over-expression of this miRNA reduced 
tumor growth, migration and invasion [49]. In the in vivo 
model, only five miRNAs are affected by trabectedin. It 
has been previously demonstrated that miR-375, found 
up-regulated in our PDX model, is a tumor suppressor in 
colon cancer and pancreatic cancer, by inhibiting PI3K/
Akt via [50, 51]. A down-regulation of miR-214 upon 
trabectedin treatment was also found; Li and collaborators 
demonstrated that its inhibition correlated with a high risk 
of metastasis increasing the transcription of TWIST. In 
our model, TWIST is slightly down-regulated, suggesting 
that miR-214 could have different mechanism of action in 
BTC [52]. The unique common microRNA up-regulated 
in both models is miR-4284. Its role is not clear, but in 
a work of Yang, miR-4284 seems to be overexpressed 
by bermamine, a natural chemotherapeutic agent, in 
glioblastoma cells; they demonstrated its role as tumor 
suppressor, promoting apoptosis in cancer stem cells of 
glioblastoma [53]. Interestingly, we found that 116 genes 
Figure 9: microRNA-target prediction analysis: In Panel A, Venn diagram showed that 66 up-regulated genes Panel C of 
our signature are predicted targets of down-regulated microRNAs. In Panel B, Venn diagram showed that 50 down-regulated genes 
Panel D of our signature are targets of up-regulated micro-RNAs.
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of our signature are predicted targets of deregulated 
microRNAs; in particular, the down-regulated gene SYK 
is target of all up-regulated microRNAs, while LGALS1 
is a putative target of miR-1207-5p, miR-1225-5p. These 
microRNAs have a role as tumor suppressors; in fact, their 
up-regulation caused a reduction of motility and invasion 
in breast and gastric cancers [54, 55], supporting our data 
on migration in BTC cell lines. These findings suggest 
further investigations to study their interaction with SYK 
and LGALS1, both involved in migration process.
In conclusion, we described that trabectedin affects 
genes and microRNAs involved in processes related 
to tumor progression and metastasis, reflecting results 
obtained at macroscopically level in BTC. We identified 
two trabectedin putative targets involved in motility and 
migration, supporting the role of trabectedin as anti-
metastatic agent. Further studies of gene-microRNA 
networking and consequent functional studies will be 
planned to investigate the complex post-transcriptional 
alterations caused by trabectedin treatment.
MATERIALS AND METHODS
Samples and drug treatment
The patient derived xenograft (PDX) was obtained 
and treated with trabectedin as previously described 
[19]. Briefly, PDX were intra venous treated with 0.15 
mg/Kg/weekly or with drug vehicle for 21 days. The 
establishment and characterization process of its paired 
cell line, MT-CHC01, is described in our recent work 
[56]. The extrahepatic cell line WITT (provided by Dr. 
Andersen, BRIC Center, Copenhagen) was cultured in 
DMEM (Sigma–Aldrich) plus 10% fetal bovine serum 
(FBS).
For gene expression and microRNA analysis, MT-
CHC01 cells (600,000/well) were plated onto 6-well tissue 
culture plates in complete Knockout/DMEM/F-12 medium 
plus 10% FBS; after 24 hours, they were treated with a 
dose of 5 nM of trabectedin, then, after further 24 hours, 
cells were detached and lysed in TRIZOL reagent for RNA 
extraction.
For cell viability assay, MT-CHC01 cells (3,000/
well) were seeded onto 96-well tissue culture plates; 
after 24 hours they were treated with escalating doses of 
trabectedin (0.019-10 nM) in appropriate culture medium 
added of 10% FBS for another 72 hours. Cell growth was 
evaluated with the Cell Titer-Glo® cell viability assay 
(Promega). All tests were performed in quadruplicate and 
repeated in three independent experiments. IC50 values, 
dose of drug that inhibits 50% of the cell growth compared 
with control calculated for each cell line after 72 hours 
of drug treatment, were calculated using the CalcuSyn 
software, based on the Chou-Talalay method. To test the 
effect of the drug on cell cycle and apoptosis, MT-CHC01 
cells were treated with 5 nM of trabectedin for 24-48 hours 
and then processed as described in our previous work [19].
Gene and microRNA expression analysis
For gene expression analysis (GEP), total RNA of 
MT-CHC01s cells and of PDX, both untreated or treated 
with trabectedin, was extracted by using the Absolutely 
RNA miRNA kit (Agilent Technologies), following 
manufacturers’ protocols. Quantitative and qualitative 
evaluation of total RNA was performed by Nanodrop 
and BioAnalyzer respectively. For GEP analysis, 100 
ng of total RNA were amplified and labeled using Low 
Input Quick Amp Labeling Kit, one-color kit (Agilent 
Technologies). Six hundred ng of labeled RNA were 
hybridized on SurePrint G3 Human Gene Expression 
8x60K v2 glass arrays. Arrays were scanned and images 
analyzed by the Feature Extraction Software from Agilent 
Technologies (version 10.7), and raw data were then 
processed using the Bioconductor package Limma (Linear 
models for microarray analysis). Background correction 
was performed with the normexp method with an offset 
of 50, and quantile was used for the between-array 
normalization. The empirical Bayes method was used to 
compute a moderated t-statistics. For microRNA analysis, 
100 ng of total RNA were labeled using the miRNA 
Complete Labeling and Hyb Kit and hybridized on Human 
miRNA Microarray Kit Release 16.0, 8x60K. Arrays were 
scanned and images analyzed by the Feature Extraction 
Software from Agilent Technologies (version 10.7). Raw 
data elaboration was carried out with Bioconductor, using 
R statistical language. Quantile was used for between-
array normalization. The Limma (LInear Models for 
Microarray Analysis) package was then used to identify 
differentially expressed micro RNAs in trabectedin-treated 
versus not treated mice or cell line. The empirical Bayes 
method was used to compute a moderated t-statistics. Gene 
expression profiling and microRNA data are available on 
GEO (GSE84939).
qRT-PCR validation
RNA was reverse-transcribed to cDNA with the 
High capacity cDNA reverse transcription kit (Applied 
Biosystem). The cDNA was used for amplification of 
CDH2, WNT7B, PMEPA1, NAV2, ATF3, NOV, CD68, 
RASD, SYK, LGALS1 deregulated genes and PGK 
housekeeping gene with specific primers (Supplementary 
Table S7). Quantitative real-time PCR was carried out in 
triplicate. Further, a validation of the expression of miR-
4284, miR 21-5p, and miR-494-3p was performed using 
TaqMan Assay. MicroRNAs expression was normalized 
on the expression of RNU48 as endogenous control. 
Quantitative analysis was performed by the measurement 
of Ct values [57].
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Gene silencing
About 600,000 MT-CHC01 and WITT cells were 
plated in a 6 multiwell plate; at about 50% of confluence, 
cells were transiently transfected using oligofectamine 
(Life Technologies) and specific siRNAs for LGALS1, 
SYK, their combination, and negative control siRNA (all 
from Sigma) at the concentration of 20 µM in Optimum 
medium without serum. After 4 hours, cells were washed 
and complete and appropriate medium for each cell line 
was replaced. After 24 hours, the SYK and LGALS1 
silencing efficiency was tested by qRT-PCR and Western 
blot analysis. Briefly, cells were detached and lysed in 
TRIZOL for RNA extraction and qRT-PCR analysis as 
previously described, and in Cell lysis buffer (Cell Signaling 
Technology, Beverly, USA) for Western blot analysis; 
homogenized cells were then centrifuged at 20,000xg for 30 
minutes; 20 μg of protein were separated with Mini-Protean 
TGX Precast Gels, 4-20%, then transferred using Trans-
Blot Turbo on nitrocellulose Midi membranes (Biorad). 
Blots were stained using standard procedures and signals 
were revealed by a chemiluminescence reagent (Euroclone, 
Milan, Italy). Primary antibody against LGALS1, SYK, 
Vinculin, and secondary anti-rabbit and anti-mouse IgG 
hrp-linked antibodies are from Cell Signaling.
Wound healing assay
After 24 hours from silencing, the confluent MT-
CHC01 and WITT cells were gently wounded with a 200 
μl tip; wound closure was monitored in each plate for 
24 hours. The gap distance was analyzed using ImageJ 
software; 0% represents the time of wound (T0). The 
percentage of closure was calculated as 100-(T/T0) x 100, 
where T represents the average wound closures at the 
different time points. Statistical analysis was performed 
using one-way ANOVA and multiple comparison test 
(GraphPad software). The assay was performed in three 
different experiments.
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